Media.Player

In vivo screening of anticancer drugs against multiple cell lines in a single live host

总结

70% of the nearly $1 billion spent on bringing each new small-molecule anticancer drug to market is spent on clinical trials. A significant part of this cost is attributed to the failure of many drugs early on in trials due to lack of efficacy. While animal models can help predict clinical efficacy in humans, these models typically only allow the testing of a drug candidate against a single cancer cell type at a time, which substantially slows the discovery process. This technology is an implantable microfluidic device that can hold dozens of live tumor spheroids generated from different cell lines, allowing simultaneous evaluation of a drug against multiple cancers in a single animal.

技术优势

High-throughput—allows multiple cell lines to be tested simultaneouslyReduces the number of animals needed for pre-clinical studiesPotentially reduces the cost and amount of time required for pre-clinical in vivo drug screeningPatent Information:Patent Pending (US 20160324991)Tech Ventures Reference: IR CU12067

技术应用

Pre-clinical in vivo screening of anticancer drugsResearch tool for determining the mechanism of action of anti-cancer dugsResearch tool for identifying causes of cancer drug resistanceTesting host response to different biomaterials

详细技术说明

None

*Abstract

None

*Inquiry

Beth KaudererColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

CU12067

*Principal Investigation

国家/地区

美国